The introduction of GM-CSF gene transduced autologous tumor vaccine (GVAX), an immunotherapeutic vaccine designed from autologous tumor cells that have been genetically modified to produce GM-CSF, has demonstrated significant potential in enhancing tumor-specific immune responses in a diverse array of cancer malignancies 37-39. The gene discussed is CSF2; the disease is neoplasm.